gastroprokinetic

Itopride hydrochloride (Ganaton) is an AChE and D2DR inhibitor.

Mosapride Citrate (TAK-370 citrate), a gastroprokinetic agent, utilizes as a selective 5HT4 agonist.

CJ 033466 is a selective partial agonist of 5-HT4 receptor (EC50 = 9 nM) with gastroprokinetic effect.

Dobupride is a novel gastroprokinetic drug.

Cinitapride Hydrogen Tartrate is a gastroprokinetic agent that acts as an antagonist of the 5-HT2 receptors and as an agonist of the 5-HT1 and 5-HT4 receptors

Acotiamide is an orally active, selective, and reversible acetylcholinesterase (AChE) inhibitor with an IC50 of 1.79 μM. It is a gastroprokinetic agent that enhances gastric contractility and accelerates delayed gastric emptying, with potential for research in functional dyspepsia involving gastric motility dysfunction and intestinal inflammatory [1] [2] [3].

Des-4-fluorobenzyl Mosapride, the main metabolite of mosapride, acts as a gastroprokinetic agent improving upper gastrointestinal (GI) motility by stimulating the serotonin receptor 4 (5-HT4; EC50= 74.2 nM, in guinea pig ileal longitudinal muscle myenteric plexus). It has been shown to increase colonic motility in dogs, horses, and guinea pigs in vivo. Mosapride, including this metabolite, is utilized in human and veterinary medicine to mitigate post-surgical and Parkinson's-induced constipation.

Cinitapride (Blaston) is a gastroprokinetic agent. It slows the actions of the muscles to reduce the symptoms of conditions such as acid reflux, delayed gastric emptying, and ulcer dyspepsia. Cinitapride acts as an antagonist of the 5-HT2 receptors and as an agonist of the 5-HT1 and 5-HT4 receptors.

Trazolopride is a compound used as an antiemetic and gastroprokinetic agent.

Mosapride N-Oxide, a major active metabolite of Mosapride, is a gastroprokinetic agent that acts as a selective 5HT4 agonist.